GLP-1 is a powerful tool, but it is a "catalyst" rather than a total solution
Drug Path: Products that claim physiological or therapeutic effects, such as promoting collagen regeneration, repairing damaged dermis, treating skin inflammation, or accelerating wound healing, are classified as drugs by the FDA
Guidance on conducting and reporting DElphi studies (CREDES) in palliative care: recommendations based on a methodological systematic review
GLP-1 delays gastric emptying via stimulating inhibitory nitrergic myenteric neurons [18] and activating vagal afferents [19], leading to reduced gastrointestinal motility [20]
Geography and Competitive Outlook North America leads early commercialization as major food companies launch GLP-1-oriented ranges and on-pack cues
However, long-term use involves: Monitoring for side effects: Common side effects include nausea, diarrhea, and injection site reactions